Novan’s Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology

MORRISVILLE, N.C., Oct. 08, 2019 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company’s Phase 2 molluscum study, designed to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum, has been published in the Journal of the American Academy of Dermatology (“JAAD”). In this Phase 2 study, SB206 demonstrated clinical efficacy with a favorable safety profile.